OncLive® On Air

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a curated list of resources to use as you study for the hematology and oncology board exams. Drs Armstrong and Tawagi discussed their personal board review plans they followed in the months leading up to boards, including the books, sections of the National Comprehensive Cancer Network Guidelines, videos, question banks, and podcasts; where you can find the “cheat sheets” they made to help them study; and the importance of personalizing your study plan based on your own knowledge and strengths. 

In today’s episode, we had the pleasure of speaking with Rory Shallis, MD, an assistant professor of medicine and hematology at Yale School of Medicine, part of Yale New Haven Health in Connecticut.

Shallis sat down with us to share some of the research that has been generated in myelodysplastic syndrome (MDS) over the past year or so, touching on the evolution of clinical trial end points and where the field is headed in terms of therapeutic classes. He also spoke to the investigation of the late-stage erythroid maturation agent luspatercept-aamt (Reblozyl) in this population in the phase 3 ELEMENT-MDS (NCT05949684) and MAXILUS (NCT06045689) trials.

In our exclusive interview, Shallis discussed the research basis for the ELEMENT-MDS trial in MDS, the potential of intervening with luspatercept before patients become red blood cell transfusion dependent, and aspects of the trial to be aware of for patient enrollment.

Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. 

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. 
In today’s episode, we had the pleasure of speaking with Tarita Thomas, MD, PhD, MBA, and Rimas Lukas, MD, about abstracts presented during a brain cancer­–focused clinical science symposium at the 2024 ASCO Annual Meeting. Dr Thomas is an associate professor of radiation oncology and Dr Lukas is an associate professor of neurology (neuro-oncology; hospital neurology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. 
In our exclusive interview, Drs Thomas and Lukas discussed the results of 4 abstracts presented during the symposium. In particular, their discussion highlighted findings with ST101 in window-of-opportunity cohorts of patients with recurrent glioblastoma (GBM), the prognostic utility of cerebrospinal fluid circulating tumor DNA in recurrent high-grade glioma, the genomic drivers of GBM, and preclinical data with navtemadlin (KRT-232) in IDH wild-type GBM. 
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. 
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. 
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! 
Thanks again for listening to OncLive On Air. 

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, sits down with Tejas Patil, MD, an assistant professor of medicine-medical oncology at the University of Colorado School of Medicine - Anschutz Medical Campus in Aurora.
In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial (NCT03521154), where treatment with osimertinib (Tagrisso) following definitive chemoradiotherapy led to an improvement in progression-free survival vs placebo in patients with stage III, EGFR-mutated non–small cell lung cancer (NSCLC).
Drs Park and Patil also explore the implications of minimal residual disease (MRD) monitoring in the phase 3 ADAURA trial (NCT02511106) and how liquid biopsy data may influence future treatment timelines. Additionally, they delve into the evolving role of osimertinib in advanced EGFR-mutated NSCLC, based on results from the phase 3 FLAURA2 trial (NCT04035486) and its potential impact on the treatment of patients with brain metastases.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. 

OncLive On Air  is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. 
In today’s episode, supported by AbbVie, we had the pleasure of speaking with Jennifer Crombie, MD, about the FDA approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma. Dr Crombie is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts.
On June 26, 2024, the FDA granted accelerated approval to epcoritamab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. This regulatory decision was supported by findings form the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which the agent yielded an overall response rate of 82% (95% CI, 74.1%-88.2%) in the primary efficacy cohort (n = 127), including a complete response rate of 60% (95% CI, 50.8%-68.4%). 
In our exclusive interview, Dr Crombie discussed the significance of this approval, key findings from the pivotal EPCORE NHL-1 trial, and where the future of the FL treatment paradigm is headed. 

___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AbbVie. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. 
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. 

OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. 
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! 
Thanks again for listening to OncLive On Air. 

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn. 

In today’s episode, we invited experts from across oncology specialties to discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Emre Yekedüz, MD, an associate professor of medical oncology at Ankara University in Turkey and a research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts, shared insights on his latest work in gastrointestinal malignancies, particularly in pancreatic and colorectal cancer.

Thach-Giao Truong, MD, a hematologist and medical oncologist at the Cleveland Clinic in Ohio who specializes in skin cancers including basal cell carcinoma, melanoma, and Merkel cell carcinoma, highlighted her recent findings in targeted therapies for advanced skin cancers.

John H. Strickler, MD, an associate professor of medicine in the Division of Medical Oncology at Duke University in Durham, North Carolina, emphasized key updates in the treatment of gastroesophageal malignancies, where he sees significant progress on the horizon.

David Spigel, MD, chief scientific officer and medical oncologist at Sarah Cannon Research Institute in Nashville, Tennessee, discussed the expanding clinical trial program he oversees, ensuring patients have access to cutting-edge therapies.

Finally, Paolo Tarantino, MD, a researcher at the European Institute of Oncology and clinical research fellow at Dana-Farber Cancer Institute, focused on advancements in breast cancer research, particularly in HER2-targeted therapies and antibody-drug conjugates.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a review session for the oncology board exams. Drs Armstrong and Tawagi discussed high-yield oncology and hematology topics to focus on during study sessions, memorization tricks they used for their own boards, and other tips for exam preparation.

In today’s episode, we had the pleasure of speaking with Narjust Florez, MD, about patient-focused lung cancer biomarker testing discussions.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.